By PETER DOSHI and TOM JEFFERSON Published: April 10, 2012 The New York Times – IN the fall of 2009, at the height of fears over swine flu, our research group discovered that a majority of clinical trial data for the anti-influenza drug Tamiflu — data that proved, according to its manufacturer, that the drug reduced the risk of hospitalization, serious complications and transmission — were missing, unpublished and inaccessible to the research community. From what we could tell from the limited clinical data that had been published in medical journals, the country’s most widely used and heavily stockpiled influenza drug appeared no more effective than aspirin. Read More
- ‘Bag of Pills’: Is It Necessary? Fewer medications is an achievable goal
- Now There’s Proof: Docs Who Get Company Cash Tend to Prescribe More Brand-Name Meds
- Let’s involve Connecticut patients in reducing medical errors
- Want to know about medical mistakes? Talk to the parents.
- Number of hospital accidents not getting any better